{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:22:52Z","timestamp":1769901772047,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40265-025-02273-y","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:30:38Z","timestamp":1768786238000},"page":"203-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Sequencing in Advanced Urothelial Cancer"],"prefix":"10.1007","volume":"86","author":[{"given":"Irbaz B.","family":"Riaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Abdullah","family":"Humayun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1552-511X","authenticated-orcid":false,"given":"Syed A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"7492","key":"2273_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322. https:\/\/doi.org\/10.1038\/nature12965.","journal-title":"Nature"},{"issue":"11","key":"2273_CR2","first-page":"1","volume":"17","author":"S Mehmeti","year":"2023","unstructured":"Mehmeti S, Limani R, Manxhuka-K\u00ebrliu S. Correlation between p53 and Rb protein expression and the Ki-67 proliferative index in urothelial carcinoma of the urinary bladder. Oncol Radiother. 2023;17(11):1\u201310.","journal-title":"Oncol Radiother"},{"issue":"6 Suppl.","key":"2273_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2022.40.6_suppl.556","volume":"40","author":"M Lattanzi","year":"2022","unstructured":"Lattanzi M, Necchi A, Sonpavde GP, Grivas P, Pal SK, et al. Incidence and clinical outcomes of HER2-altered bladder cancer. J Clin Oncol. 2022;40(6 Suppl.):556.","journal-title":"J Clin Oncol"},{"key":"2273_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12967-020-02308-w","volume":"18","author":"W Fang","year":"2020","unstructured":"Fang W, Yang ZY, Chen TY, Shen XF, Zhang C. Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020;18:145. https:\/\/doi.org\/10.1186\/s12967-020-02308-w.","journal-title":"J Transl Med"},{"issue":"7","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(7):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"19","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Loriot Y, et al. CheckMate 901 Trial Investigators. Nivolumab plus gemcitabine-cisplatin in previously untreated advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"key":"2273_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102900","volume":"134","author":"E Grande","year":"2025","unstructured":"Grande E, Hussain SA, Barth\u00e9l\u00e9my P, Benjamin DJ, Hoffman J, Birtle A, et al. Individualizing first-line treatment for advanced urothelial carcinoma: a favorable dilemma for patients and physicians. Cancer Treat Rev. 2025;134:102900. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102900.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"2273_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103725","volume":"9","author":"AB Apolo","year":"2024","unstructured":"Apolo AB, Bellmunt J, Cordes L, Gupta S, Powles T, Rosenberg JE, et al. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria. ESMO Open. 2024;9(9):103725. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103725.","journal-title":"ESMO Open"},{"key":"2273_CR9","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): bladder cancer. Version 1.2024. Plymouth Meeting (PA): NCCN; 2024. Available from: https:\/\/cdn.mednet.co.il\/2024\/02\/Bladder-cancer-NCCN-Jan-2024.pdf. [Accessed 21 Aug 2025]."},{"key":"2273_CR10","doi-asserted-by":"publisher","first-page":"10914","DOI":"10.1038\/s41467-024-55331-6","volume":"15","author":"PA Bannier","year":"2024","unstructured":"Bannier PA, Saillard C, Mann P, Hofman P, Ili\u00e9 M, Butori C, et al. AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. Nat Commun. 2024;15:10914. https:\/\/doi.org\/10.1038\/s41467-024-55331-6.","journal-title":"Nat Commun"},{"issue":"12","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1159\/000533866","volume":"101","author":"JT J\u00f8rgensen","year":"2023","unstructured":"J\u00f8rgensen JT. The potential of trastuzumab deruxtecan as a tissue-agnostic drug. Oncology. 2023;101(12):836\u201342. https:\/\/doi.org\/10.1159\/000533866.","journal-title":"Oncology"},{"issue":"17","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;27(17):4685\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2273_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14796694.2025.2482363","volume":"21","author":"M Sternschuss","year":"2025","unstructured":"Sternschuss M, Rosenberg JE. Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer. Future Oncol. 2025;21(11):1333\u201348. https:\/\/doi.org\/10.1080\/14796694.2025.2482363.","journal-title":"Future Oncol"},{"issue":"11 Suppl.","key":"2273_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/OP.2023.19.11_suppl.11","volume":"19","author":"C Ike","year":"2023","unstructured":"Ike C, Kongnakorn T, Tichy E, Benedict A, Sanchez Alvarez J, Kearney M. Healthcare costs associated with first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. JCO Oncol Pract. 2023;19(11 Suppl.):11. https:\/\/doi.org\/10.1200\/OP.2023.19.11_suppl.11.","journal-title":"JCO Oncol Pract"},{"issue":"17","key":"2273_CR15","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin plus cisplatin in patients with bladder cancer. J Clin Oncol. 2000;18(17):3068\u201373. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2273_CR16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41416-023-02543-0","volume":"130","author":"RJ Jones","year":"2024","unstructured":"Jones RJ, Crabb SJ, Linch M, Birtle AJ, McGrane J, Enting D, et al. Systemic anticancer therapy for urothelial carcinoma: UK oncologists\u2019 perspective. Br J Cancer. 2024;130(5):897\u2013907. https:\/\/doi.org\/10.1038\/s41416-023-02543-0.","journal-title":"Br J Cancer"},{"issue":"3","key":"2273_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.21037\/tau-23-576","volume":"13","author":"KK Zarrabi","year":"2024","unstructured":"Zarrabi KK, Miron B, Geynisman DM. Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses. Transl Androl Urol. 2024;13(3):463\u20136. https:\/\/doi.org\/10.21037\/tau-23-576.","journal-title":"Transl Androl Urol"},{"issue":"10","key":"2273_CR18","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1007\/s12325-023-02624-9","volume":"40","author":"A Mansinho","year":"2023","unstructured":"Mansinho A, Cruz A, Marconi L, Pinto C, Augusto I, Gil A, et al. Avelumab as first-line maintenance treatment in locally advanced or metastatic urothelial carcinoma: a review of guideline recommendations and expert position. Adv Ther. 2023;40(10):4134\u201350. https:\/\/doi.org\/10.1007\/s12325-023-02624-9.","journal-title":"Adv Ther"},{"issue":"36 Suppl.","key":"2273_CR19","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.19.01213","volume":"38","author":"PH O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell PH, Grivas P, Balar AV, Castellano D, Galsky MD, Hahn NM, et al. Long-term efficacy and safety of pembrolizumab monotherapy in cisplatin-ineligible metastatic urothelial carcinoma: extended follow-up of KEYNOTE-052. J Clin Oncol. 2020;38(36 Suppl.):4524. https:\/\/doi.org\/10.1200\/JCO.19.01213.","journal-title":"J Clin Oncol"},{"key":"2273_CR20","unstructured":"UroToday. ESMO 2025: disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la\/mUC) with HER2 expression. UroToday. 2025. Available from: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2025\/esmo-2025-bladder-cancer\/164110-esmo-2025-disitamab-vedotin-dv-plus-toripalimab-t-versus-chemotherapy-c-in-first-line-1l-locally-advanced-or-metastatic-urothelial-carcinoma-la-muc-with-her2-expression.html. (Accessed 14 Dec 2025)."},{"key":"2273_CR21","unstructured":"ASCO Daily News Staff. Nivolumab plus chemotherapy shows durable disease control, improved survival in lymph node-only metastatic urothelial carcinoma. ASCO Daily News. 2024. Available from: https:\/\/dailynews.ascopubs.org\/do\/nivolumab-plus-chemotherapy-shows-durable-disease-control-improved-survival-lymph-node. (Accessed 14 Dec 2025)."},{"issue":"16 Suppl.","key":"2273_CR22","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1200\/JCO.2025.43.16_suppl.4571","volume":"43","author":"J Bedke","year":"2025","unstructured":"Bedke J, Powles TB, Valderrama BP, Sridhar SS, Vaishampayan UN, Gurney H, et al. EV-302: long-term subgroup analysis from the phase III global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC). J Clin Oncol. 2025;43(16 Suppl.):4571. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4571.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2273_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2023.01.005","volume":"6","author":"SH Song","year":"2023","unstructured":"Song SH, Roe KG, Kim JC. Advances in peri-operative immunotherapy and treatment failures in muscle-invasive urothelial carcinoma. Eur Urol Oncol. 2023;6(4):390\u20138. https:\/\/doi.org\/10.1016\/j.euo.2023.01.005.","journal-title":"Eur Urol Oncol"},{"issue":"16 Suppl.","key":"2273_CR24","first-page":"4505","volume":"41","author":"T Friedlander","year":"2023","unstructured":"Friedlander T, Milowsky MI, Balar AV, Loriot Y, Sternberg CN, Vuky J, et al. Updated results from cohort K of the EV-103 (KEYNOTE-869) trial: enfortumab vedotin plus pembrolizumab in first-line cisplatin-ineligible metastatic urothelial carcinoma. J Clin Oncol. 2023;41(16 Suppl.):4505.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2273_CR25","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Sternberg CN, Park YH, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"key":"2273_CR26","doi-asserted-by":"publisher","first-page":"175883592410287","DOI":"10.1177\/1758835924102873","volume":"16","author":"WA Kwon","year":"2024","unstructured":"Kwon WA, Choi JH, Lee SH, Joung JY, Seo HK, Chung J, et al. Evolving treatment landscape of first-line therapy for metastatic urothelial carcinoma: the paradigm shift to enfortumab vedotin plus pembrolizumab. Ther Adv Med Oncol. 2024;16:1758835924102873. https:\/\/doi.org\/10.1177\/1758835924102873.","journal-title":"Ther Adv Med Oncol."},{"key":"2273_CR27","doi-asserted-by":"publisher","first-page":"175883592412955","DOI":"10.1177\/17588359241295544","volume":"17","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Liu K, Zhu H, Li S, Yuan D. Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis. Ther Adv Med Oncol. 2025;17:17588359241295544. https:\/\/doi.org\/10.1177\/17588359241295544.","journal-title":"Ther Adv Med Oncol"},{"key":"2273_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, Albiges L, Tomczak P, Su\u00e1rez C, Voss MH, de Velasco G, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for renal cell carcinoma after progression on prior immune checkpoint inhibitor therapy (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402:185\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(23)00922-4.","journal-title":"Lancet"},{"issue":"10","key":"2273_CR29","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.21037\/tau-21-123","volume":"10","author":"VS Koshkin","year":"2021","unstructured":"Koshkin VS, Osbourne AS, Grivas P. Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review. Transl Androl Urol. 2021;10(10):4022\u201335. https:\/\/doi.org\/10.21037\/tau-21-123.","journal-title":"Transl Androl Urol"},{"issue":"12","key":"2273_CR30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/onco.13925","volume":"26","author":"RL Wong","year":"2021","unstructured":"Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, et al. Efficacy of platinum rechallenge in metastatic urothelial carcinoma after previous platinum-based chemotherapy for metastatic disease. Oncologist. 2021;26(12):1026\u201334. https:\/\/doi.org\/10.1002\/onco.13925.","journal-title":"Oncologist"},{"key":"2273_CR31","doi-asserted-by":"publisher","first-page":"1151701","DOI":"10.3389\/fonc.2022.1151701","volume":"13","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wang H, Deng Y, Yao R, Zou X, Zhang F, et al. Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: a systematic review and meta-analysis. Front Oncol. 2023;13:1151701. https:\/\/doi.org\/10.3389\/fonc.2022.1151701.","journal-title":"Front Oncol"},{"key":"2273_CR32","doi-asserted-by":"publisher","first-page":"1266890","DOI":"10.3389\/fphar.2023.1266890","volume":"14","author":"T Yuan","year":"2023","unstructured":"Yuan T, Li F, Hou Y, Guo H. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study. Front Pharmacol. 2023;14:1266890. https:\/\/doi.org\/10.3389\/fphar.2023.1266890.","journal-title":"Front Pharmacol"},{"issue":"12","key":"2273_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122246","volume":"16","author":"S Rodler","year":"2024","unstructured":"Rodler S, Aydogdu C, Brinkmann I, Berg E, Kopliku R, G\u00f6tz M, et al. Toxicity-induced discontinuation of immune checkpoint inhibitors in metastatic urothelial cancer: 6-year experience from a specialized uro-oncology center. Cancers (Basel). 2024;16(12):2246. https:\/\/doi.org\/10.3390\/cancers16122246.","journal-title":"Cancers (Basel)"},{"issue":"17 Suppl","key":"2273_CR34","doi-asserted-by":"publisher","first-page":"LBA4619","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","volume":"41","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Phase 3 THOR study: results of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with selected FGFR alterations. J Clin Oncol. 2023;41(17 Suppl):LBA4619. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA4619.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2273_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34(11):1047\u201354. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.016.","journal-title":"Ann Oncol"},{"issue":"2","key":"2273_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.euf.2024.05.011","volume":"10","author":"JR Brown","year":"2024","unstructured":"Brown JR. Therapies after progression on enfortumab vedotin and pembrolizumab: navigating second-line options for metastatic urothelial carcinoma in the new treatment landscape. Eur Urol Focus. 2024;10(2):231\u20133. https:\/\/doi.org\/10.1016\/j.euf.2024.05.011.","journal-title":"Eur Urol Focus"},{"key":"2273_CR37","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/OTT.S364734","volume":"15","author":"N Sayegh","year":"2022","unstructured":"Sayegh N. Clinical evidence and selecting patients for treatment with erdafitinib. Onco Targets Ther. 2022;15:2311\u201320. https:\/\/doi.org\/10.2147\/OTT.S364734.","journal-title":"Onco Targets Ther"},{"issue":"21","key":"2273_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215431","volume":"14","author":"AB Katims","year":"2022","unstructured":"Katims AB, Reisz PA, Nogueira L, Truong H, Lenis AT, Pietzak EJ, et al. Targeted therapies in advanced and metastatic urothelial carcinoma. Cancers (Basel). 2022;14(21):5431. https:\/\/doi.org\/10.3390\/cancers14215431.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2273_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","volume":"195","author":"C Oing","year":"2016","unstructured":"Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C. Second-line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond \u2014 a comprehensive review of the current literature. J Urol. 2016;195(2):254\u201363. https:\/\/doi.org\/10.1016\/j.juro.2015.06.115.","journal-title":"J Urol"},{"issue":"5","key":"2273_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14728214.2025.2517581","volume":"25","author":"T Unekawa","year":"2025","unstructured":"Unekawa T, \u00d6zdemir BC, Kogan M, Powles T, Bellmunt J. The role of HER2-targeted therapy in urothelial carcinomas. Expert Rev Anticancer Ther. 2025;25(5):501\u201312. https:\/\/doi.org\/10.1080\/14728214.2025.2517581.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"2273_CR41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s12325-024-02975-x","volume":"41","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Abad S, Llombart-Cussac A, Gil-Mart\u00ednez I, Rodr\u00edguez-Mart\u00edn C, Marquez-Rodas I, et al. Post hoc analysis of the DESTINY-PanTumor02 trial demonstrates durable responses to trastuzumab deruxtecan in patients with HER2 IHC 2+ or 3+ solid tumors. Adv Ther. 2024;41(8):1165\u201378. https:\/\/doi.org\/10.1007\/s12325-024-02975-x.","journal-title":"Adv Ther"},{"key":"2273_CR42","unstructured":"ClinicalTrials.gov. IZABRIGHT-Bladder01: izalontamab (BL-B01D1) versus platinum-based chemotherapy in previously treated urothelial carcinoma. ClinicalTrials.gov Identifier: NCT07106762. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07106762. (Accessed 14 Dec 2025)."},{"issue":"Suppl. 9","key":"2273_CR43","doi-asserted-by":"publisher","first-page":"LBA9","DOI":"10.1016\/annonc\/0923-7534(24)04946-9","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Grivas P, Vulsteke C, Grande E, Gupta S, Sternberg CN, et al. A randomized phase III study of sacituzumab govitecan vs chemotherapy in pretreated advanced urothelial carcinoma (TROPiCS-04): final overall survival and safety results. Ann Oncol. 2024;35(Suppl. 9):LBA9. https:\/\/doi.org\/10.1016\/annonc\/0923-7534(24)04946-9.","journal-title":"Ann Oncol"},{"issue":"1","key":"2273_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2273_CR45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.clgc.2024.01.001","volume":"22","author":"A Soares","year":"2024","unstructured":"Soares A, Bourlon MT, Wong A, Joshi A, Jardim D, Korbenfeld E, et al. Management of metastatic urothelial carcinoma in emerging markets (EM): an expert opinion. Clin Genitourin Cancer. 2024;22(2):467\u201375. https:\/\/doi.org\/10.1016\/j.clgc.2024.01.001.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2273_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.euo.2023.08.009","volume":"7","author":"SH Tolmeijer","year":"2024","unstructured":"Tolmeijer SH, van Wilpe S, Geerlings MJ, von Rhein D, Smilde TJ, Kloots ISH, et al. Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer. Eur Urol Oncol. 2024;7(2):282\u201391. https:\/\/doi.org\/10.1016\/j.euo.2023.08.009.","journal-title":"Eur Urol Oncol"},{"issue":"16 Suppl.","key":"2273_CR47","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2025.43.16_suppl.4560","volume":"43","author":"K Reyes","year":"2025","unstructured":"Reyes K, Jindal T, Mitchell B, Zhu X, et al. Circulating tumor DNA (ctDNA) monitoring in patients with advanced urothelial carcinoma treated with enfortumab vedotin \u00b1 pembrolizumab. J Clin Oncol. 2025;43(16 Suppl.):4560. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4560.","journal-title":"J Clin Oncol"},{"key":"2273_CR48","doi-asserted-by":"publisher","first-page":"1574449","DOI":"10.3389\/fimmu.2025.1574449","volume":"16","author":"Q Ma","year":"2025","unstructured":"Ma Q, Hou S, Ma H, Gao J, Song D. Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Front Immunol. 2025;16:1574449. https:\/\/doi.org\/10.3389\/fimmu.2025.1574449.","journal-title":"Front Immunol"},{"key":"2273_CR49","unstructured":"BioSpace. BioAtla and Context Therapeutics announce exclusive worldwide license agreement to develop and commercialize BA3362, a Nectin-4 \u00d7 CD3 T-cell engaging antibody. BioSpace. 2024. Available from: https:\/\/www.biospace.com\/press-releases\/bioatla-and-context-therapeutics-announce-exclusive-worldwide-license-agreement-to-develop-and-commercialize-ba3362-a-nectin-4-x-cd3-t-cell-engaging-antibody. (Accessed 14 Dec 2025)."},{"key":"2273_CR50","unstructured":"National Institute for Health and Care Excellence (NICE). Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable. London: NICE; 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11233. (Accessed 25 Aug 2025)."},{"key":"2273_CR51","unstructured":"Natera, Inc. IMvigor011 bladder cancer trial achieves positive results, with Signatera\u2122 strongly predicting adjuvant immunotherapy benefit. Austin (TX): Natera, Inc.; 2025. Available from: https:\/\/www.natera.com\/news\/imvigor011-bladder-cancer-trial-achieves-positive-results. (Accessed 14 Dec 2025)."},{"key":"2273_CR52","unstructured":"National Cancer Institute. MODERN: an integrated phase 2\/3 trial of MRD-based optimization of adjuvant therapy in urothelial cancer (NCT05987241). Bethesda (MD): U.S. National Library of Medicine; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05987241. (Accessed 25 Aug 2025)."},{"issue":"20","key":"2273_CR53","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Tran NK, Zsch\u00e4bitz S, Hahn O, B\u00fcttner T, Roghmann F, et al. Nectin4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer. J Clin Oncol. 2024;42(20):2446\u201355. https:\/\/doi.org\/10.1200\/JCO.23.01983.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02273-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02273-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02273-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:58:01Z","timestamp":1769849881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02273-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02273-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Irbaz B. Riaz and Muhammad Abdullah Humayun have no conflicts of interest that are directly relevant to the content of this article. Ali Raza Khaki has received research funding to his institution from 23 and Me, Acrivon Therapeutics, Janssen, and Pfizer. Syed A. Hussain has received research funding from CR UK, MRC\/NIHR, UHB charities, CCC charities, Northwest Cancer Research, Yorkshire Cancer Research, Weston Park Cancer Charity, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre, Eli Lilly, and Roche and was on the advisory board or a consultant for Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Merck, and Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MAH: manuscript writing, figure, tables. SAH: manuscript writing, figure, tables. IBR: manuscript writing, figure, tables. ARK: manuscript writing, figure, tables.\u00a0All authors have read the final manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}